Liquid chromatography/tandem mass spectrometry study of forced degradation of azilsartan medoxomil potassium
- 5 July 2015
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 29 (15) , 1437-1447
Abstract
Rationale: Azilsartan medoxomil potassium (AZM) is a new antihypertensive drug introduced in the year 2011. The presence of degradation products not only affects the quality, but also the safety aspects of the drug. Thus, it is essential to develop an efficient analytical method which could be useful to selectively separate and identify the degradation products of azilsartan medoxomil potassium. Methods: AZM was subjected to forced degradation under hydrolytic (acid, base and neutral), oxidative, photolytic and thermal stress conditions. Separation of the drug and degradation products was achieved by a liquid chromatography (LC) method using an Acquity UPLC ® C18 CSH column with mobile phase consisting of 0.02% trifluoroacetic acid and acetonitrile using a gradient method. Identification and characterization of the degradation products was carried out using LC/electrospray ionization quadrupole time‐of‐flight mass spectrometry (ESI‐QTOFMS). Results: A total of five degradation products (DP 1 to DP 5) were formed under various stress conditions and their structures were proposed with the help of tandem mass spectrometry (MS/MS) experiments and accurate mass data. A common degradation product (DP 4) was observed under all the degradation conditions. DP 1, DP 2 and DP 5 were observed under acid hydrolytic conditions whereas DP 3 was observed under alkaline conditions. Conclusions: AZM was found to degrade under hydrolytic, oxidative and photolytic stress conditions. The structures of all the degradation products were proposed. The degradation pathway for the formation of degradation products was also hypothesized. A selective method was developed to quantify the drug in the presence of degradation products which is useful to monitor the quality of AZM. Copyright © 2015 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Azilsartan/chlorthalidone combination therapy for blood pressure controlIntegrated Blood Pressure Control, 2013
- Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramiprilJournal of Human Hypertension, 2013
- Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartanHypertension Research, 2012
- Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic HypertensionHypertension, 2012
- Azilsartan Medoxomil: A New Angiotensin II Receptor Antagonist for Treatment of HypertensionAnnals of Pharmacotherapy, 2011
- Azilsartan Medoxomil: A New Angiotensin Receptor BlockerClinical Therapeutics, 2011
- Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure MonitoringThe Journal of Clinical Hypertension, 2011
- Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008Pharmacoepidemiology and Drug Safety, 2010
- Allergic reactions to ampicillin. Studies on the specificity and selectivity in subjects with immediate reactionsClinical & Experimental Allergy, 1997
- Allergic reactions to ampicillin. Studies on the specificity and selectivity in subjects with immediate reactionsClinical & Experimental Allergy, 1997